Cg Oncology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.3%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
-$3.22next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| BLA Submission Completion for HR BCG-Unresponsive NMIBC | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly1.1BTarget: Sufficient to fund operations through 2029
Cretostimogene BOND-003 Complete Response Rate (Monotherapy) Annually76.0%Target: FDA BLA Approval
Cretostimogene CORE-008 Cohort CX Complete Response Rate (Combination with Gemcitabine) Annually92.0%Target: Establish combination backbone efficacy
Watch Items
- Biologics License Application (BLA) Submission for High-Risk BCG-Unresponsive NMIBCTrigger: Completion of the remaining CMC module and final submissionAction: Monitor FDA acceptance and potential filing review timeline in Q4 2026
- PIVOT-006 Phase 3 Topline DataTrigger: Topline data readout for intermediate-risk NMIBCAction: Evaluate recurrence-free survival (RFS) risk reduction compared to surveillance
- CORE-008 Cohort CX 12-Month Durability DataTrigger: Presentation of 12-month combination dataAction: Assess long-term durability of complete responses for cretostimogene plus gemcitabine
Research as of 19 Jun 2026